About us

“Our new brand will be front and center as we continue making a difference to patients, to physicians, and to healthcare systems. It’s exciting and it’s just the first step in what will be a landmark year for ResMed, with launches of game-changing products and solutions.”

Mick Farrell, CEO ResMed

At ResMed, we believe that every breath is a gift.
And from the day we began pioneering sleep apnea treatment in 1989, our purpose has been to spread awareness and deliver life-changing products and solutions to patients suffering from sleep-disordered breathing and other respiratory conditions.

More than twenty-five years later, we’re unveiling a new brand that reinforces our stance as an industry leader and, more importantly, our commitment to improving lives.
To reflect our updated brand, we’ve refreshed our company website for the US and updated our logo.

The blue-to-red pulse curve not only symbolizes the transition from deoxygenated to oxygenated blood with every breath and beat of the heart, but it represents the very reason we are here today as an organization; to make every breath another chance for positive change.

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases.
ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

Our Vision and Our Mission

Our Vision is to be the global solutions leader for SDB, COPD and other major chronic diseases. Our Mission is to improve the quality of life for patients, prevent progression of chronic diseases, and reduce overall healthcare system costs.

Aims and objectives

We are a global leader in the development, manufacturing and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing.

We sell a comprehensive range of products in more than 100 countries worldwide through direct offices and a network of distributors.

We are committed to advancing innovative technology in sleep and respiratory medicine and commercializing innovative products incorporating these technologies on a global basis. In reaching our goals, we will at all times act ethically in dealing with both customers and employees.

The ResMed story

In 1981 Professor Colin Sullivan and colleagues at the University of Sydney described and developed nasal continuous positive airway pressure (CPAP), the first successful non-invasive treatment for obstructive sleep apnoea (OSA).

After publishing the successful results in Lancet, Sullivan, who had patented the technology, sought a compatible partner to help commercialise this life-changing technology. In 1986 he approached Chris Lynch, Managing Director of the Baxter Centre for Medical Research and Vice President of R&D for Baxter Healthcare, who in turn reached out to his Baxter co-worker Dr. Peter Farrell.

In 1987 Farrell, on behalf of Baxter, invested in Sullivan’s technology to further evolve the CPAP prototype and undertake clinical trials on a group of patients with severe sleep apnoea. In 1989, after Baxter decided not to enter the sleep apnoea market for a variety of reasons, Farrell founded ResMed (short for “Respiratory Medicine”) to buy Sullivan’s sleep technology from Baxter and to commercialise his prototype CPAP device to allow scalable device production – in other words, to bring CPAP to the world at large.

Since then, ResMed has delivered on Farrell’s promise: making CPAP masks, CPAP machines and in-home life support ventilators more comfortable, quieter and easier to use. It has also become the world leader in remote and self-monitoring software, with more than three million patients worldwide remotely monitored by clinicians. The software is shown to increase patients’ therapy adherence rates and clinicians’ business efficiencies.